- $13.22m
- -$14.85m
- 25
- 49
- 80
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.48 | ||
| Price to Tang. Book | 0.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -70.88% | ||
| Return on Equity | -48.74% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Directors
- Steven Hanley CHM (53)
- Alex Ovadia CEO (59)
- Mira Rosenzweig CFO (49)
- Yoav Kimchy CTO (60)
- Joshua Belkar VOP (52)
- Hanit Brenner-lavie VPR
- Israel Hershko VPR (55)
- Boaz Shpigelman VRD (49)
- Clara Ezed IND (49)
- Mary Jo Gorman IND (61)
- XiangQian Lin IND (37)
- Yuval Yanai IND (69)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- April 5th, 2009
- Public Since
- February 19th, 2015
- No. of Shareholders
- 51
- No. of Employees
- 85
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 5,849,216
- Address
- 29 Abba Hushi Ave., Isfiya, 3009000
- Web
- https://check-cap.com/
- Phone
- +972 48303401
- Contact
- Irina Koffler
- Auditors
- Brightman Almagor Zohar & Co
Upcoming Events for CHEK
Q1 2024 Check Cap Ltd Earnings Release
Q2 2024 Check Cap Ltd Earnings Release
Similar to CHEK
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Check Cap share price?
As of Today at 19:05 UTC, shares in Check Cap are trading at $2.26. This share price information is delayed by 15 minutes.
How has the Check Cap share price performed this year?
Shares in Check Cap last closed at $2.26 and the price had moved by +63.77% over the past 365 days. In terms of relative price strength the Check Cap share price has outperformed the S&P500 Index by +36.28% over the past year.
What are the analyst and broker recommendations for Check Cap?
The overall consensus recommendation for Check Cap is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Check Cap dividend yield?
Check Cap does not currently pay a dividend.
Does Check Cap pay a dividend?
Check Cap does not currently pay a dividend.
When does Check Cap next pay dividends?
Check Cap does not currently pay a dividend.
How do I buy Check Cap shares?
To buy shares in Check Cap you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Check Cap?
As of the previous close price of $2.26, shares in Check Cap had a market capitalisation of $13.22m.
Where are Check Cap shares listed?
Here are the trading details for Check Cap:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CHEK
What kind of share is Check Cap?
Based on an overall assessment of its quality, value and momentum Check Cap is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Check Cap share price forecast for 2024?
The analyst consensus target price for shares in Check Cap is $7.00. That is 209.73% above the last closing price of $2.26.
Analysts covering Check Cap currently have a consensus Earnings Per Share (EPS) forecast of -$3.25 for the next financial year.
What is the trend in the Check Cap share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Check Cap. Over the past six months, its share price has underperformed the S&P500 Index by -40.6%.
As of the last closing price of $2.26, shares in Check Cap were trading -19.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Check Cap PE Ratio?
The Check Cap PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Check Cap?
Check Cap's management team is headed by:
- Steven Hanley - CHM
- Alex Ovadia - CEO
- Mira Rosenzweig - CFO
- Yoav Kimchy - CTO
- Joshua Belkar - VOP
- Hanit Brenner-lavie - VPR
- Israel Hershko - VPR
- Boaz Shpigelman - VRD
- Clara Ezed - IND
- Mary Jo Gorman - IND
- XiangQian Lin - IND
- Yuval Yanai - IND